News

Diving for novel antibiotics
Enlarge image

ResearchEUBelgiumUK

Diving for novel antibiotics

15.02.2013 - The EU-project PharmaSea will bring researchers to some of the deepest, coldest and hottest places on the planet in the hunt for novel antibiotics.

Scientists from the UK, Belgium, Norway, Spain, Ireland, Germany, Italy, Switzerland and Denmark will work together to collect and screen samples of mud and sediment from huge, previously untapped, oceanic trenches. The large-scale, four-year project is backed by more than €9.5 million of EU funding and brings together 24 partners from 14 countries from industry, academia and non-profit organisations.

The PharmaSea project focuses on biodiscovery research and the development and commercialisation of new bioactive compounds from marine organisms, including deep-sea sponges and bacteria, to evaluate their potential as novel drug leads or ingredients for nutrition or cosmetic applications. The international team of scientists is led by Professor Marcel Jaspars of the University of Aberdeen in Scotland, and coordinated by Dr. Camila Esguerra of the University of Leuven in Belgium.

Only a handful of samples have ever been taken from deep trenches and investigated, so the project is breaking new ground. "PharmaSea will not only be exploring new territory at the bottom of the oceans, but also new areas in ‘chemical space’. With our broad platform of cutting-edge bioassays to detect drug-like activity, we'll be testing many unique chemical compounds from these marine samples that have literally never seen the light of day. We're quite hopeful that we'll find a number of exciting new drug leads", says Dr. Camila Esguerra, Industrial Research Fellow and Lecturer with the Laboratory for Molecular Biodiscovery at the University of Leuven.

The international team will employ strategies commonly used in the salvage industry to carry out the sampling. Using fishing vessels, researchers will drop a sampler on a reel of cables to the trench bed to collect sediment. Scientists will then attempt to grow unique bacteria and fungi from the sediment that can be extracted to isolate novel drug-like molecules for pharmacological testing. Partners from China, Chile, Costa Rica, New Zealand and South Africa will support the PharmaSea project. The first field tests will be carried out next autumn in the Atacama Trench in the Eastern Pacific Ocean, about 100 miles off the coast of Chile and Peru. The team will also search the Arctic waters off Norway and the Antarctic via Italian and South African partners. Deep trenches will also be accessed off New Zealand and China.

Marine organisms that live more than 6,000 meters below the sea level are considered to be an interesting source of novel bioactive compounds as they survive under extreme conditions. "Trenches are separated from each other and represent islands of diversity. They are not connected to each other and life has evolved differently in each one", explains Marcel Jaspars. 

© eurobiotechnews.eu/al

http://www.european-biotechnology-news.com/news/news/2013-01/plunging-new-depths-for-novel-antibiotics.html

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.

R&DNetherlandsSpainAustria

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

    FLOP

      TOP

        FLOP

          TOP

            FLOP

              No liability assumed, Date: 06.07.2015